$PG

3 Dividend Stocks to Buy Before August Ends and Hold for Life

Procter & Gamble (PG) reported fiscal 2026 earnings with $6.89 EPS and $87.03B revenue, announcing a $10B+ capital return plan. PepsiCo (PEP) posted Q2 2026 revenue of $24.18B, highlighting strong international growth. Coca-Cola (KO) saw Q2 2026 volume growth of 5% and raised full-year guidance, benefiting from World Cup momentum.

Original reporting
Published Aug 23, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 23, 2026, 2:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
3 Dividend Stocks to Buy Before August Ends and Hold for Life — source image
Decision brief

The 30-second read

$PGBullishMed
01

Why it matters

Fresh earnings data and dividend hikes provide new material for income‑focused traders, suggesting modest buying opportunities.

02

Market read

Strong earnings and dividend guidance reinforce the attractiveness of dividend‑heavy consumer staples, likely supporting sector performance.

03

What to watch

Potential cost headwinds in FY2027 and slower North American demand for PEP could temper gains.

Relevance 8/10Novelty 8/10Timing: post‑Q2 2026 earnings release

Background

The article reviews three Dividend Kings—PG, PEP, KO—after their Q2 2026 earnings releases, emphasizing dividend growth and capital return plans.

Company-level read

Ticker impact

$PGBullishHigh confidence
Context

PG reported FY2026 core EPS $6.89 and announced a $10B dividend plan for FY2027.

Expected impact

Potential modest upside as yield becomes more attractive.

Evidence & confidence

Large-cap with solid cash flow and new dividend guidance; market may price in higher yield.

$PEPBullishHigh confidence
Context

PEP posted Q2 2026 revenue $24.18B, raised dividend to $1.48 and outlined $8.9B capital return plan.

Expected impact

Likely modest rally on income appeal.

Evidence & confidence

Quarterly earnings beat and increased payout signal financial health.

$KOBullishMedium confidence
Context

KO delivered Q2 2026 organic revenue growth 6%, raised full-year guidance and highlighted World Cup marketing boost.

Expected impact

Short-term upside, especially ahead of ex-dividend date.

Evidence & confidence

Share price already up >30% YTD; earnings reinforce bullish trend.

Market effects

Highlights strength of consumer staples dividend sector, may lift peers.

U.S. income‑focused investors likely to reallocate toward these dividend kings.

World Cup marketing boost for KO shows global branding impact on earnings.

Counterpoint

High valuations and forward P/E multiples could limit upside despite dividend appeal.

Key entities

  • Procter & Gamble

    Consumer staples giant with 70‑year dividend streak.

  • PepsiCo

    Food & beverage company extending 54‑year dividend streak.

  • Coca‑Cola

    Beverage leader with 60‑plus year dividend streak and World Cup catalyst.

Related articles

$KOMedAI 8/10

Governor Hochul, the Coca-Cola Company and Fairlife Celebrate Ramp Up at $650 Million, State-of-the-Art Dairy Production Facility in Monroe County

The Coca-Cola Company's fairlife has opened a $650M dairy facility in Monroe County, NY, creating 380 jobs and processing 5-6M lbs of milk daily. Governor Hochul highlighted the state's dairy leadership and support for local farmers. The project received $21M in state assistance and $20M for wastewater upgrades.

$KOMed

Dividend King pays Warren Buffett's Berkshire $848M each year

Coca-Cola (KO) increased its dividend to $2.12 per share, marking 64 consecutive years of dividend growth. Berkshire Hathaway, owned by Warren Buffett, receives $848 million annually from its 400 million shares. KO reported strong Q2 results, with free cash flow of $6.9 billion and raised its full-year outlook. Analysts have raised price targets, with Barclays, TD Cowen, and RBC Capital all increasing their targets.

$LLYMed

This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G

UK MHRA approved Eli Lilly’s once-daily oral GLP-1 orforglipron (Foundayo) on 10 Aug 2026 for weight loss and weight maintenance in adults meeting BMI criteria. Bristol Myers Squibb plans a US$2.3bn Houston manufacturing campus within a US$40bn US investment. Novo Nordisk hired Omnicom for US media, ending WPP, and partnered with AWS on AI drug discovery. P&G is expanding Health Care after its US$3.8bn Thorne acquisition.